Immunosuppression in liver transplant recipients with renal impairment

Journal of Hepatology

Volumn 54, Issue 5, 2011, Pages 1041-1054

  Duvoux, C ^a   Pageaux, G P ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

CNI toxicity; Immunosuppression; Liver transplantation; Renal dysfunction; Renal failure

Indexed keywords

ANGIOTENSIN II; AZATHIOPRINE; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; ENDOTHELIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN E2; RAPAMYCIN; TACROLIMUS; THROMBOXANE A2; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE KIDNEY TUBULE NECROSIS; ADRENERGIC SYSTEM; ALBUMINURIA; ARTERIOLAR VASOCONSTRICTION; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT REJECTION; HEMATURIA; HEPATITIS C; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER GRAFT; MAINTENANCE THERAPY; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SURVIVAL; T LYMPHOCYTE ACTIVATION; URINE VOLUME; VASOCONSTRICTION;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY, CHRONIC;

EID: 79954856358     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.12.001     Document Type: Review

References (92)

1. D.S. Fraley, R. Burr, J. Bernardini, D. Angus, D.J. Kramer, and J.P. Johnson Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation Kidney Int 54 1998 518 524 (Pubitemid 28357414)
2. J. McCauley, D.H. Van Thiel, T.E. Starzl, and J.B. Puschett Acute and chronic renal failure in liver transplantation Nephron 55 1990 121 128 (Pubitemid 20167918)
3. E.Q. Lima, D.M. Zanetta, I. Castro, P.C. Massarollo, S. Mies, and M.M. Machado Risk factors for development of acute renal failure after liver transplantation Ren Fail 25 2003 553 560 (Pubitemid 36944734)
4. I. Bilbao, R. Charco, J. Balsells, J.L. Lazaro, E. Hidalgo, and L. Llopart Risk factors for acute renal failure requiring dialysis after liver transplantation Clin Transpl 12 1998 123 129 (Pubitemid 128721313)
5. J.B. Cabezuelo, P. Ramirez, A. Rios, F. Acosta, D. Torres, and T. Sansano Risk factors of acute renal failure after liver transplantation Kidney Int 69 2006 1073 1080 (Pubitemid 43372183)
6. S. Karie-Guigues, N. Janus, F. Saliba, J. Dumortier, C. Duvoux, and Y. Calmus Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens [calcineurin inhibitors alone or in combination with mycophenolate mofetil]: the TRY study Liver Transpl 15 2009 1083 1091
7. J. Guitard, O. Cointault, N. Kamar, F. Muscari, L. Lavayssiere, and B. Suc Acute renal failure following liver transplantation with induction therapy Clin Nephrol 65 2006 103 112 (Pubitemid 43224483)
8. T.A. Gonwa, M.L. Mai, and L.B. Melton End-Stage Renal Disease [ESRD] after Orthotopic Liver Transplantation [OLTX] using calcineurin-based imminotherapy risk of development and treatment Transplantation 72 2001 1934 1939 (Pubitemid 34027867)
9. T.A. Gonwa, M.L. Mai, L.B. Melton, S.R. Hays, R.M. Goldstein, and M.F. Levy Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis Transplantation 71 2001 1424 1428 (Pubitemid 32507116)
10. C.M. Wyatt, and R.R. Arons The burden of acute renal failure in nonrenal solid organ transplantation Transplantation 78 2004 1351 1355 (Pubitemid 39507975)
11. G. Contreras, G. Garces, A.A. Quartin, C. Cely, M.A. LaGatta, and G.A. Barreto An epidemiologic study of early renal replacement therapy after orthotopic liver transplantation J Am Soc Nephrol 13 2002 228 233 (Pubitemid 34042032)
12. N. Singh, T. Gayowski, and M.M. Wagener Post transplantation dialysis-associated infections: morbidity and impact on outcome in liver transplant recipients Liver Transpl 7 2001 100 105 (Pubitemid 32166514)
13. A. Rueggeberg, S. Boehm, F. Napieralski, A.R. Mueller, P. Neuhaus, and K.J. Falke Development of a risk stratification model for predicting acute renal failure in orthotopic liver transplantation recipients Anaesthesia 63 2008 1174 1180
14. A.O. Ojo, P.J. Held, and F.K. Port Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 931
15. A.O. Ojo Renal disease in recipients of non renal solid organ transplantation Semin Nephrol 27 2007 498 507 (Pubitemid 47002073)
16. E. Velidedeoglu, R.D. Bloom, M.D. Crawford, N.M. Desai, L. Campos, and P.L. Abt Early kidney dysfunction post liver transplantation predicts late chronic kidney disease Transplantation 77 2004 553 556 (Pubitemid 38282811)
17. V. Schmitz, S. Laudi, and F. Moeckel Chronic renal dysfunction following liver transplantation Clin Transplant 22 2008 333
18. A.J. Olyaei, M. Angelo, A.M. de Mattos, M. William, and W.M. Bennett Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies Curr Opin Crit Care 7 2001 384 389 (Pubitemid 34020400)
19. N.A. Bobadilla, and G. Gamba New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone Am J Physiol Renal Physiol 293 2007 F2 F9
20. N. Perico, A. Benigni, E. Bosco, M. Rossini, S. Orisio, and F. Ghilardi Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins? Clin Nephrol 25 Suppl. 1 1986 S83 S88
21. N.A. Bobadilla, E. Tapia, M. Franco, P. Lopez, S. Mendoza, and R. Garcia-Torres Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity Kidney Int 46 1994 773 779 (Pubitemid 24272035)
22. V. Kon, M. Sugiura, T. Inagami, B.R. Harvie, I. Ichikawa, and R.L. Hoover Role of endothelin in cyclosporine-induced glomerular dysfunction Kidney Int 37 1990 1487 1491 (Pubitemid 20198030)
23. T.A. Gonwa, G.B. Klintmalm, and M. Levy Impact of pre-transplant renal function on survival after liver transplantation Transplantation 59 1995 361
24. H.J. Schlitt, A. Barkmann, K.H. Boker, H.H. Schmidt, N. Emmanouilidis, and J. Rosenau Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study Lancet 357 2001 587 591 (Pubitemid 32179611)
25. G. Orlando, L. Baiocchi, A. Cardillo, G. Iaria, N. De Liguori Carino, and L. De Luca Switch to 1.5 grams MPA monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension Liver Transpl 13 2007 46 54 (Pubitemid 46099973)
26. P. De Simone, H.J. Metselaar, L. Fischer, J. Dumortier, K. Boudjema, and J. Hardwigsen Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial Liver Transpl 15 2009 1262 1269
27. F. Vincenti, C. Larsen, Wekerle.T. Durrbach, B. Nashan, G. Blancho, and P. Lang Costimulation blockade with belatacept in renal transplantation N Engl J Med 353 2005 770 781 (Pubitemid 41215486)
28. T. Soliman, H. Hetz, C. Burghuber, G. Gyori, G. Silberhumer, and R. Steininger Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation Liver Transpl 13 2007 1039 1044 (Pubitemid 47189018)
29. T. Soliman, H. Hetz, C. Burghuber, G. Györi, G. Silberhumer, and R. Steininger Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation Transpl Int 20 2007 447 452 (Pubitemid 46535988)
30. I. Bajjoka, L. Hsaiky, K. Brown, and M. Abouljoud Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors Liver Transpl 14 2008 66 72 (Pubitemid 351167991)
31. C. Lin, F.R. Chuang, and C.H. Lee The renal-sparing efficacy of basiliximab in adult living donor liver transplantation Liver Transpl 11 2005 1258 1264 (Pubitemid 41511941)
32. E.M. Yoshida, P.J. Marotta, P.D. Greig, N.M. Kneteman, D. Marleau, and M. Cantarovich Evaluation of renal function in liver transplant recipients receiving daclizumab [Zenapax], mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial Liver Transpl 11 2005 1064 1072 (Pubitemid 41341755)
33. J.M. Neuberger, R.D. Mamelok, P. Neuhaus, J. Pirenne, D. Samuel, and H. Isoniemi The ReSpECTStudy Group. Delayed Introduction of Reduced-Dose Tacrolimus, and Renal Function in Liver Transplantation: The 'ReSpECT' Study Am J Transplant 9 2009 327 336
34. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461
35. G. Garcia-Tsao, C.R. Parikh, and A. Viola Acute Kidney Injury in Cirrhosis Hepatology 48 2008 2064 2077
36. S.A. Farkas, A.A. Schnitzbauer, G. Kirchner, A. Obed, B. Banas, and H.J. Schlitt Calcineurin inhibitor minimization protocols in liver transplantation Transpl Int 22 2009 49 60
37. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
38. A.S. Levey, K.U. Eckardt, and Y. Tsukamoto Definition and classification of chronic kidney disease: a position statement from kidney disease: Improving Global Outcomes [KDIGO] Kidney Int 67 2005 2089 2100 (Pubitemid 41623371)
39. N.C. Fisher, P.G. Nightingale, B.K. Gunson, G.W. Lipkin, and J.M. Neuberger Chronic renal failure following liver transplantation: a retrospective analysis Transplantation 66 1998 59 66 (Pubitemid 28341169)
40. P.A. Sheiner, J.F. Magliocca, and C.A. Bodian Long-term medical complications in patients surviving > or = 5 years after liver transplant Transplantation 69 2000 781 789 (Pubitemid 30174097)
41. G.I. Slapak, R. Saxena, and B. Portmann Graft and systemic disease in long-term survivors of liver transplantation Hepatology 25 1997 195 202 (Pubitemid 27015010)
42. A.J. Cohen, M.D. Stegall, and C.B. Rosen Chronic renal dysfunction late after liver transplantation Liver Transpl 8 2002 916 921 (Pubitemid 35154021)
43. A. O'Riordan, V. Wong, P.A. McCormick, J.E. Hegarty, and A.J. Watson Chronic kidney disease post-liver transplantation Nephrol Dial Transplant 21 2006 2630 2636 (Pubitemid 44644543)
44. P. Burra, M. Senzolo, and A. Masier Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study Dig Liver Dis 41 2009 350 356
45. M. Naesens, D.R.J. Kuypers, and M. Sarwal Calcineurin inhibitor nephrotoxicity Clin L Am Soc Nephrol 4 2009 481 508
46. B.S. Collins, C.L. Davis, C.L. Marsh, J.P. McVicar, J.D. Perkins, and C.E. Alpers Reversible cyclosporine arteriolopathy Transplantation 54 1992 732 734
47. R. Bahirwani, and K.J. Reddy Outcomes after liver transplantation: chronic kidney disease Liver Transpl 15 2009 S70 S74
48. E. Pillebout, D. Nochy, and G. Hill Renal histopathological lesions after orthotopic liver transplantation Am J Transpl 5 2005 1120 1129 (Pubitemid 40571263)
49. J.M. Moreno, V. Cuervas-Mons, and E. Rubio Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality Transplant Proc 35 2003 1907 1908 (Pubitemid 37093759)
50. M. Cantarovich, G.N. Tzimas, J. Barkun, M. Deschenes, E. Alpert, and J. Tchervenkov Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction Transplantation 76 2003 98 102 (Pubitemid 36877122)
51. R.O. Koch, I.W. Graziadei, and F. Schulz Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction Transpl Int 17 2004 518 524 (Pubitemid 39592738)
52. D.J. Reich, P.A. Clavien, and E.Z. Hodge Mycophenolate Mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results Transplantation 80 2005 18 25 (Pubitemid 40980890)
53. C. Creput, F. Blandin, and B. Deroure Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation Liver Transpl 13 2007 1004 1010 (Pubitemid 47163193)
54. G.P. Pageaux, L. Rostaing, and Y. Calmus Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation Liver Transpl 12 2006 1755 1760 (Pubitemid 44920019)
55. V.R. Cicinnati, Z. Yu, and C.G. Klein Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - assessment of renal and allograft function, cardiovascular risk factors and immune monitoring Aliment Pharmacol Ther 26 2007 1195 1208 (Pubitemid 47620415)
56. M. Biselli, G. Vitale, and A. Gramenzi Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant Clin Transplant 23 2009 191 198
57. A. Barkmann, B. Nashan, and H.H. Schmidt Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of cacineurin inhibitors by mycophenolate mofetil Transplantation 69 2000 1886 1890 (Pubitemid 30340350)
58. M.L. Raimondo, L. Dagher, G.V. Papatheodoridis, N. Rolando, D.W. Patch, and B.R. Davidson Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation Transplantation 75 2003 186 190 (Pubitemid 36139669)
59. J.M. Moreno Planas, V. Cuervas-Mons, and E. Rubio Gonzalez Mycophenolate Mofetil can be used as monotherapy late after liver transplantation Am J Transplant 4 2004 1650 1655 (Pubitemid 39312299)
60. S. Dharancy, A. Lannelli, and A. Hulin Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation Am J Transplant 9 2009 610 613
61. K.D. Fairbanks, J.A. Eustace, J.A. Fine, and P.J. Thuluvath Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus Liver Transpl 9 2003 1079 1085 (Pubitemid 37304464)
62. C.J. Watson, A.E. Gimson, and G.J. Alexander A randomized controlled trial of late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function Liver Transpl 13 2007 1694 1702
63. S. Shenoy, K.L. Hardinger, and J. Crippin Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial Transplantation 83 2007 1389 1392 (Pubitemid 46800318)
64. M.S. Campbell, J. Rai, E. Kozin, R.D. Bloom, J.F. Markmann, and K.M. Olthoff Effects of sirolimus vs. Calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation Clin Transplant 21 2007 377 384 (Pubitemid 46711401)
65. D. DuBay, R.J. Smith, and K.G. Qiu Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens Liver Transpl 14 2008 651 659 (Pubitemid 351696277)
66. J.F. Castroagudin, E. Molina, and R. Romero Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with renal dysfunction Liver Transpl 15 2009 1792 1797
67. K.D. Fairbanks, and P.J. Thuluvath Mycophenolate monotherapy in liver transplant recipients: a single center experience Liver Transpl 10 2004 1189 1194 (Pubitemid 39248419)
68. M. Brunet, I. Cirera, and J. Martorell Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant recipients treated with mycophenolate mofetil Transplantation 81 2006 541 546
69. W.J. Sandborn, J.E. Hay, and M.K. Porayko Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection Hepatology 19 1994 925 932 (Pubitemid 24109355)
70. C.Y. Chan, K. DasGupta, and A.L. Baker Cyclosporin A: drug discontinuation for the management of long-term toxicity after liver transplantation Hepatology 24 1996 1085 1089 (Pubitemid 26365908)
71. M. Hong, P.W. Angus, R.M. Jones, R.B. Vaughan, and P.J. Gow Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction Clin Transplant 19 2005 193 198 (Pubitemid 40424889)
72. A.K. Burroughs, G. Germani, M. Pleguezuelo, F. Villamil, S. Vaghjiani, and E. Tsochatzisa Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil Am J Transplant 9 2009 1725 1731
73. A.H. Cotterell, R.A. Fisher, A.L. King, T.W.B. Gehr, S. Dawson, and R.K. Sterling Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent Clin Transplant 16 2002 49 51 (Pubitemid 41185585)
74. S. Nair, J. Eason, and G. Loss Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients Liver Transpl 9 2003 126 129 (Pubitemid 36204562)
75. A. Maheshawari, M.S. Torbenson, and P.J. Thuluvath Sirolimus monotherapy versus sirolimus in combination with steroids and/or MPA for immunosuppression after liver transplantation Dig Dis Sci 51 2006 1677 1684
76. E.Q. Sanchez, A.P. Martin, T. Ikegami, T. Uemura, G. Narasimhan, and R.M. Goldstein Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years Transplant Prod 37 2005 4416 4423 (Pubitemid 43016046)
77. I. Morard, J. Dumortier, L. Spahr, A. Hadengue, P. Majno, and P. Morel Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients Liver Transpl 13 2007 658 664 (Pubitemid 46796536)
78. G.W. Neff, M. Montalbano, G. Slapak-Green, D. Meyer, T. Berney, and K. Safdar Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency Transplant Proc 35 2003 3029 3031 (Pubitemid 38102122)
79. G.S. Jensen, A. Wiseman, and J.F. Trotter Sirolimus conversion for renal preservation in livrer transplantation: not so fast Liver Transplant 14 2008 601 603 (Pubitemid 351696269)
80. F.P. Schena, M.D. Pascoe, J. Alberu, M. del Carmen Rial, R. Oberbauer, and D.C. Brennan Neylan JF; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233 242
81. V. Bumbea, N. Kamar, and D. Ribes Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus Nephrol Dial Transplant 20 2005 2517 2523 (Pubitemid 41548881)
82. J.R. Chapman, and G.K. Rangan Why do patients develop proteinuria with sirolimus? Do we have the answer? Am J Kidney Dis 55 2010 213 216
83. B.M. McGuire, B.A. Julian, J.S. Bynon Jr, W.J. Cook, S.J. King, and J.J. Curtis Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation Ann Intern Med 144 2006 735 741 (Pubitemid 46780633)
84. C. Duvoux, A. Tran Ngoc, L. Intrator, C. Hézode, G. Germanidis, and J.M. Pawlotsky Dhumeaux D Hepatitis C virus (HCV)-related cryoglobulinemia after liver transplantation for HCV cirrhosis Transpl Int 15 2002 3 9 (Pubitemid 36055892)
85. E.A. Kendrick, J.P. McVicar, K.V. Kowdley, P. Bronner, M.J. Emond, and C.E. Alpers Renal disease in hepatitis C-positive liver transplant recipients Transplantation 63 1997 1287 1293 (Pubitemid 27212824)
86. H.P. Pham, C. Féray, D. Samuel, M. Gigou, D. Azoulay, and V. Paradis Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients Kidney Int 54 1998 1311 1319 (Pubitemid 28449920)
87. G.A. Abrahamian, A.B. Cosimi, M.L. Farrell, D.A. Schoenfeld, R.T. Chung, and M. Pascual Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation Liver Transpl 6 2000 185 190 (Pubitemid 30173998)
88. A. Kornberg, B. Küpper, J. Wilberg, A. Tannapfel, K. Thrum, and E. Bärthel Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients Transpl Infect Dis 9 2007 295 301 (Pubitemid 350059145)
89. J. Lake, D. Patel, K. David, J. Richwine, and J. Morris The association between MPA and risk of progressive renal dysfunction and death in adult liver transplant recipients with HCV Clin Transplant 23 2009 108 115
90. J. Dumortier, S. Bernard, and Y. Bouffard Boillot O Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus Liver Transpl 12 2006 659 664
91. M. Martínez-Llordella, J.J. Lozano, I. Puig-Pey, G. Orlando, G. Tisone, and J. Lerut Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients J Clin Invest 118 2008 2845 2857
92. Duvoux C, Marquet P. The MONOCEPT Study: interruption of the calcineurin inhibitors [CNI] and introduction of mycophenolate mofetil [MPA] in liver transplant patients with side effects due to CNI: study of the reduction of the risks of rejection by MPA therapeutic drug monitoring; Clinical Trials.gov identifier: NCT00456235.